The multisite trial, widely used in mental health research and education, enables experimenters to assess the average impact of a treatment across sites, the variance of treatment impact across sites, and the moderating effect of site characteristics on treatment efficacy. Key design decisions include the sample size per site and the number of sites. To consider power implications, this article proposes a standardized hierarchical linear model and uses rules of thumb similar to those proposed by J. Cohen (1988) for small, medium, and large effect sizes and for small, medium, and large treatment-by-site variance. Optimal allocation of resources within and between sites as a function of variance components and costs at each level are also considered. The approach generalizes to quasiexperiments with a similar structure. These ideas are illustrated with newly developed software.
sampled per site, the number of sites, and the possibility of incorporating site-level covariates to account for site variation in treatment effects. Sampling a large number of persons per site will increase the precision of the treatment effect estimate at each site.
However, if the treatment effect varies substantially over sites, having a large number of sites will be important for inferences about the average impact of the treatment. Yet the more the treatment impact varies from site to site, the less interesting the average treatment effect becomes. It therefore is important to estimate both the mean and the variance of the treatment effect across sites. It also may be important to study moderator effects: The treatment may be especially effective at certain kinds of sites. A choice of sample size of participants per site, say n, and of the sample size of sites, say J, might be adequate for estimating certain parameters (e.g., the mean and variance of the treatment effect) and inadequate for estimating other parameters (e.g., the association between type of site and expected treatment effect). In contemplating such design choices, one cannot ignore costs. It may, for example, be far more expensive to sample a new site than to sample an additional participant within a site. The problem of research design is thus considerably more complicated for the multisite experiment than for the single-site experiment.
Below, we consider the determinants of power for detecting the main effect of treatment, the treatmentby-site variance, and the moderating effect of a site characteristic on the treatment effect. We then consider the problem of design. In the case of balanced designs, choosing a design involves two sample sizes: the number of participants per site and the number of sites. But these choices are constrained by the relative cost of sampling at each level. We address this problem by adopting the strategy of optimal allocation of resources.
Optimal allocation has a venerable tradition in survey research in which the design problem involves choosing, for example, optimal cluster sizes and the optimal number of clusters in a multistage cluster design (Cochran, 1977; Kish, 1965) . Psychologists have used the same principles in constructing measurement instruments for which tradeoffs arise, for example, between the number of items and number of occasions of measurement in maximizing the reliability of the test (Cleary & Linn, 1969; Marcoulides, 1997) . Methodologists have recently advocated the optimal allocation strategy for all features of experimental design in psychology, including the number of participants per treatment in an experimental design, the number of replicate observations per participant, and the choice of covariates (McClelland, 1997; Allison, Allison, Faith, Paultre, & Pi-Sunyer, 1997) . Our approach closely parallels optimal allocation as applied to the cluster randomized trial, in which key tradeoffs involve the number of participants per cluster and the number of clusters per treatment (Jeanpretre & Kraftsik, 1989; Overall & Dalai, 1965; Raudenbush, 1997) .
In the case of the multisite trial, the interplay between the variation in the treatment effect across sites and the cost of sampling at each level drives optimal allocation.
To achieve these goals and to make the results applicable over many possible applications, we construct a standardized model for the data produced in a multisite trial. The model includes a standardized effect size measure, as is now common (e.g., Cohen, 1988) , but it also includes standardized measures of site-by-treatment variance and of site-level moderating effects. We propose rules of thumb for deciding whether site-by-treatment variation and moderating effects are "small," "medium," or "large," and illustrate by example how assumptions about these parameters and about cost affect optimal allocation of resources and power.
To elucidate key concepts, we restrict our attention in this article to balanced designs, continuously measured dependent variables, and the case of two treatment groups, which we label the experimental group and the control group. However, the general model and approach can readily be extended to more complex settings.
Statistical Model and Tests

A Hierarchical Linear Model
We find it convenient and illuminating to formulate the linear model for the multisite trial as a hierarchical linear model (HLM). The formulation facilitates construction of a standardized model that is useful for planning studies and extends easily to the case of unbalanced designs and continuous or discrete covariates measured on participants or sites. Following the procedure of Raudenbush (1993) 
where P 0; -is the mean outcome for site j; X l} is a treatment contrast, with a value of 0.5 for members of the experimental group and -0.5 for members of the control group, /' = !,...,»; (Jy is thus the mean difference between outcomes of experimental and control groups within sitey; and r tj is a person-specific residual assumed independently and normally distributed within sites, with constant variance a 2 .
Level 2 model. Within the framework of the HLM, the coefficients at Level 1 become outcome variables at Level 2. Thus, the site mean and the sitespecific treatment effect vary randomly across sites according to the model
Here, 700 is the grand mean outcome and "yi 0 is the average treatment effect; u 0 j and «, y are site-specific random effects that are independent of r^ and are assumed to have a bivariate normal distribution over sites, that is, The combined model is widely termed a "mixed model," with fixed effects -y^, -y 10 , random effects «q/> Uy and a within-cell residual r lf Some software packages encourage users to specify the model in its hierarchical formulation, as in Equations 1 and 2 (e.g., HLM [Raudenbush, Bryk, Cheong, & Congdon, 2000] [Littell, Milliken, Stroup, & Wolfinger, 1996] and Mixed Reg [Hedeker & Gibbons, 1996] In words, the unconditional variance Dgg of the site mean estimate is the sum of two components: the variance of the true mean and the variance of the estimate given the true mean. The conditional variance D[, of the treatment effect across sites has a similar structure.
Estimation affixed effects.
In an unbalanced design, with varying sample sizes across sites, the estimators of fixed effects would be precision-weighted averages (cf. Bryk & Raudenbush, 1992, chap. 3) . In a balanced design, the grand mean and average treatment effects are estimated by simple averages: 
A«-2)
Estimates of the variance components are as follows:'
The sampling variances of these fixed effects estimated are and (13)
Hypothesis Tests
Of key interest in the multisite trial are the average treatment effect, 7 01 , otherwise known as the main effect of treatment, and the variance of the treatment effect, T U , otherwise known as the treatment-by-site variance.
Average treatment effect.
Under the null hypoth- . The covariance 7 01 is similarly estimated by subtraction. On occasion, this covariance estimate, in combination with the variance estimates, will produce a correlation with an absolute value exceeding 1.0. Then the T OI estimate may be set to the value that corresponds to the correlation with an absolute value 1.0. Consideration of these boundary value cases, though important in data analysis, has no special bearing on planning a study, the topic of interest in this article.
where F 
Standardized Model for Two Groups
There are good reasons to translate our general model for the multisite trial into a model that includes standardized effect sizes (Cohen, 1988; Glass, 1976) and their variance. In the case of the multisite trial, however, it is not enough to specify a standardized effect size for the main effect of treatment. As we have seen above, the variance of the treatment impact across sites is also of interest, not only in itself, but also in determining power and sample sizes for inferences regarding the main effect. We therefore need to extend Cohen's (1988) approach by introducing a standardized metric for treatment-by-site variance.
In the context of our two-group model for site J, let us standardize the within-treatment, within-site variance to o-2 = 1.0. Then the treatment effect for site j becomes a standardized effect size 8,, that is, the standardized mean difference between experimental and control groups according to the Level 1 model -0.30 and 0.50, the variability would be large. In each case, the specified range is roughly two standard deviations, implying a probability in excess of 0.68 that a site-specific standardized effect size would fall in the specified range. It is, of course, a trivial matter to redefine these rules of thumb, but the current definitions will serve our purposes of illustration in the present article.
Main Effect of Treatment
The computation of power for the average treatment effect is straightforward. As mentioned, the test as n increases without bound, holding J constant, power approaches a bound less than 1.0 ( Figure 1A ).
This will always be the case unless the variance of the treatment effect is null. Third, the importance of n in increasing power depends strongly on the variance of the treatment effect: the larger this variance component, the less important is n for increasing power.
Variance of the Treatment Effect
Computation of power for the variance of the treatment effect is again straightforward, although the test 
Multisite Trials With Site Characteristics as Moderators
The results of the previous section have somewhat ironic implications for design. Given nonzero variability in treatment effects across sites, increasing the impact of the treatment effect. Thus, to the extent treatment effects are context-specific, it becomes scientifically important to understand the characteristics of context that account for such variation. The search for such moderators is equivalent to the search in meta-analysis for study characteristics that account for variation in findings between studies (cf. Hedges, 1994; Raudenbush, 1994) .
ELM.
We can readily elaborate the HLM to include site characteristics that might account for effectsize variation over sites. Because such characteristics vary at Level 2, that is, over sites, they become explanatory variables in the Level 2 model. The Level 1 model remains as before (Equation 19 ), whereas the Level 2 model is elaborated (in the case of a single study characteristic) to be «oj (23) where F follows the noncentral F-distribution with df -1, / -2, and the noncentrality parameter where W, is a site covariate with a mean of 0.0; -y,,, is the average standardized treatment effect across sites;
•yu is association between the site covariate, Wj, and the effect at site j; Vart.Uy) = o-j; is the residual variance of the standardized site means; Var(«y) = o| is the residual variance of standardized treatment effect across sites; and Cov(u OJ , «y) = a u?> is the covariance between the standardized site mean and treatment effect, holding constant W,. Thus, Wj is a measured characteristic of site./ that is hypothesized to account for variation in study effect sizes. We also include Wj in the model for site means. A failure to specify the effect of W, on the site mean might cause a misspecification of the model for the contribution of Wj to the treatment effect (Bryk & Raudenbush, 1992, chap. 9 ) because the random effects (« 0y , My) of the two Level 2 equations are correlated. Of interest are power and sample size requirements for inferences about y n , the moderating effect of Wj on the effect size.
Power and sample sizes. Basic principles for testing the moderating effect of the site characteristic closely parallel those for detecting the main effects of treatment. For example, consider the case in which sites are of two types, with each type consisting of J/2 sites. The estimate of 7,, is thus the difference in average treatment effect between two types of sites, namely,
where 8^ is the estimate of standardized treatment effect at the^'th site. Statistical inference closely parallels that for the main effect of treatment, so we omit the details. The null hypothesis H 0 : 7 U = 0 can be tested by computing r " 2 F(1,/-2;X) = ^, (25) 4o-s (26) Power for detecting the moderating effect of a site characteristic depends on the magnitude of the residual site-by-treatment variance. Although increasing n increases power, increasing / is more important; and this relative importance of J is greatest when the residual site-by-treatment variance is large. Our hope, of course, is that W } will be a strong predictor of the effect size, such that the residual site-by-treatment variance will be small. We can, of course, test the hypothesis that this residual variance is null.
Optimal Allocation of Resources
Figures 1 and 2 display important trade-offs in designing multisite trials, trade-offs between the number of participants per site and the number of sites. We see from Figure 1 that for estimating the main effect of treatment, maximizing J, the number of sites, has a greater impact on power than does maximizing n, the number of participants per site. Testing moderating effects of site characteristics has similar implications; J is more important than n in maximizing power for detecting these moderating effects. Although these results seem to favor designs with many sites and few participants per site, such a design may be infeasible. It may be very expensive to add each additional site, whereas adding participants per site may be comparatively inexpensive. Thus, given the total resources available for the research, the number of sites that can be recruited is sharply constrained. Moreover, including a large n helps substantially in estimating the treatment-in-site variance. How, then, should resources be allocated within and between sites to optimize power? The answer to this question would depend on whether the aim is to make inferences about (a) the main effect of treatment, (b) the magnitude of the treatment-by-site variance, or (c) the moderating effect of site characteristics.
In each case, we consider a simple linear cost function:
where T is the total variable cost of the study; C is the cost of sampling a site; and C, is the cost of sampling a participant within a site. Thus, the number of sites, J, is a function of the total resources available for the study and of n, the number of participants per site:
Our strategy is to choose "optimal n," that is, the number of participants per site that maximizes the noncentrality parameter in the power function given T and the hypothesized model parameters. J is then determined by inequality 28. Of course, in each case, we investigate optimal n, ], and power over a range of possible parameter estimates. We shall see that optimizing n for one purpose (maximizing power for the test of the main effect of treatment) will not, in general, optimize n for another purpose (e.g., estimating the variance of the treatment effect). Thus, in practice, it is necessary to weigh the relative importance of the various parameters that might be estimated and to ensure that power is at least adequate for all moderately important purposes. Let us consider each key parameter in turn.
Average Effect of Treatment
Our discussion of Figure 1 suggested that having a large J is particularly important when the site-bytreatment variance is large. However, the temptation to maximize J must be tempered by the relative cost ratio C/C,, that is, the incremental cost of sampling a new site relative to the incremental cost of sampling a person within an already-sampled site. When we maximize power for the main effect of treatment, subject to the cost constraint (Equation 27), we see precisely how this logic plays out. The optimal n is then 4
Equation 29 parallels the well-known formula for the optimal cluster size in a two-stage cluster sample (Cochran, 1977) and the optimal sample size per cluster in a cluster randomized trial with no covariates (cf. Allison et al., 1997; Overall & Dalai, 1965; Waters & Chester, 1987; Raudenbush, 1997) . We see that optimal n is directly proportional to the square root of the cost ratio C/C, and inversely proportional to the square root of the treatment-by-site variance. Given optimal n, the number of sites, J, is then determined by T, the total resources for the study, that is,
Consider a hypothetical example with T -500 and C,, implying that if the study were a single-site study, the investigators could afford a sample size of 500. Table 1 gives the optimal n, J, and power for varying values of the cost ratio and the variance of the treatment effect. We see from Table 1 that (a) the greater the cost of sampling sites relative to sampling participants within sites, the larger the optimal n per site, yielding fewer sites; (b) the more variable the treatment effect across sites, the smaller the optimal n, allowing more sites; and (c) a large main effect size, a small cost ratio, and a small treatment-by-site variance contribute to enhanced power for detecting the main effect of treatment. However, optimizing the study for the power of detecting the main effect of treatment does not optimize it for detecting treatmentby-site variance (compare trends in power between the last two columns of Table 1 ). Note that, from the medium (0.5) to the large (0.8) effect size, power is usually very high. It is less sensitive to the cost ratio and effect size variability. A design with moderate n and J is close to the optimal design in terms of power.
The designs in Table 1 
Moderating Effect of a Site Characteristic
Now the question is whether a specific, measured characteristic of a site predicts the magnitude of the treatment effect at that site. In the language of the HLM, we are interested in the relationship between a Level 1 "slope" (the treatment effect at site j) and a Level 2 predictor, as described by the Level 2 model (see Equation 23 ). In this setting, J is more influential than n whenever the residual site-by-treatment variance is non-null. Again, however, the temptation simply to maximize J in designing the study must be tempered by C/C,, the cost of sampling sites relative to the cost of sampling participants within sites. We therefore choose the optimal n per site that will maxiThe computed optimal n is rounded to the nearest even integer to maintain a balanced design. Also, J is the largest possible number of sites, given n, such that the total cost of the study does not exceed 7*. 4 We derive Equation 29 by substituting J = r/(C,n + C)
into the formula X = rc,/o 2 /(«o^ + 4) and maximizing X with respect to n. a The computed optimal n is rounded to its nearest even integer, * The computed J is rounded. The total cost may slightly exceed the budget. For example, the seventh row has n = 12 and J = 36. The total cost will be 504. If we round the computed J down to 35, then the total cost will be 490. To meet the budget exactly, a researcher might add an additional site with only g people or use 32 sites with 12 people at each site, plus 4 sites with 10 people at each site. We therefore use rounding of J for computing consistency and simplicity. The provided power values should be close to the real power in those cases and can therefore be used as reference.
mize power given the cost ratio and the magnitude of Again let us consider a hypothetical example with T = 500. Suppose that sites are classified into two groups (e.g., urban sites vs. rural sites) on the basis of the hypothesis that the magnitude of the treatment effect depends on this site characteristic (e.g., urban
sites are hypothesized to have smaller treatment effects than are rural sites). Table 2 gives the optimal n, J, and power for varying values of the cost ratio and the variance of the treatment effect.
We see from Table 2 that optimal n and J depend on the cost ratio and the variance of the treatment effect, just as in the average treatment effect (Table   1) . Similarly, power increases as the cost ratio decreases, the variance of the treatment effect decreases, and the effect size increases. Generally, however, more data are needed to detect the moderating effect of a site characteristic than to detect the average effect of treatment, with the other factors held constant (compare power for site covariate effect in Table 2 to power for treatment-by-site variance in Table 1 ).
Discussion
The multisite trial enables experimenters to assess the average impact of a treatment across varied settings and the variability of the treatment impact across 8  8  8  8  12  12  12  12  12  12  14  14  14  20  20  20  16  16  16  20  20  20  28  28  28  24  24  24  28  28  28  40  40  40   J   50  50  50  50  50  50  36  36  36  29  29  29  26  26  26  20  20  20  19  19  19  17  17  17  13  13  13  11  11  11  10  10 to vary from site to site, it is typically useful to examine site characteristics that moderate the treatment effect. In this way, the multisite trial is a kind of planned meta-analysis, with each site contributing a "study" of the treatment impact, and the synthesis of findings across sites allowing for a study of the conditions under which the treatment appears most promising. It must be kept in mind that studies of the moderating effect of site characteristics on treatment effects are nonexperimenal (unless sites can be randomly assigned to characteristics). Nevertheless, the multisite trial can go well beyond the single-site trial in facilitating a study of generalizability of the treatment effect.
As this article has shown, costs and variance components drive the trade-off between maximizing the number of participants per site and maximizing the number of sites. If the goal is to maximize power in testing the average effect of treatment (or to minimize the length of the confidence interval for treatment impact), the logic is clear. The larger the variation in the treatment impact across sites, the more sites are needed to attain adequate power. However, the wish to maximize the number of sites will typically be constrained by cost: the larger the cost of sampling sites (relative to sampling participants within sites), the larger the optimal sample size per site needed to maximize power. A similar logic holds in maximizing power of tests of the moderating effect of a site characteristic. That is, adding sites is more consequential for power than is adding participants per site, and this advantage is greatest when the residual variation in the treatment impact across sites is large. Again, however, cost considerations cannot be ignored; and the desire to include many sites is tempered by the relative cost of sampling sites. This article has illustrated how these considerations can facilitate optimal design by using appropriate software.
However, the multiple purposes of a multisite trial create potential dilemmas in allocating resources. Optimizing the design to detect the main effect of treatment or the moderating effect of a site characteristic does not typically optimize the design for estimating the magnitude of the variance of the treatment effect. In the current article we have limited our study to continuous outcomes, balanced designs, equal costs at each site (and for each treatment within each site), and the case of two treatments per site. Extensions to more general cases, including discrete outcomes, unbalanced designs, multiple treatments, and unequal costs are important. However, we can anticipate that the logic of optimal design and power determination will extend quite naturally to this broader class of cases.
